Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Lynne Garrity-Ryan"'
Autor:
Antoni Torres, Lynne Garrity-Ryan, Courtney Kirsch, Judith N. Steenbergen, Paul B. Eckburg, Anita F. Das, Marla Curran, Amy Manley, Evan Tzanis, Paul C. McGovern
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss , Pp 501-509 (2021)
Objective: Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (
Externí odkaz:
https://doaj.org/article/86f71153138b4a8c861b7b0a6e1e71ba
Publikováno v:
JAC-Antimicrobial Resistance
Objectives To evaluate the effect of sub-growth-inhibitory concentrations of omadacycline on Staphylococcus aureus ATCC 10832 haemolytic activity in vitro. Methods Following determination of the MICs of omadacycline and comparator antibiotics, the st
Autor:
Oasis Investigators, Elliot Shin, Anita Das, Lynne Garrity-Ryan, William O'Riordan, Amy Manley, Paul C. McGovern, Judith N. Steenbergen, Evan Loh, Alissa Sirbu, Paul B. Eckburg, Evan Tzanis, Carrie Cardenas
Publikováno v:
The Lancet Infectious Diseases. 19:1080-1090
Summary Background Pathogen resistance and safety concerns limit oral antibiotic options for the treatment of acute bacterial skin and skin structure infections (ABSSSI). We aimed to compare the efficacy and safety of once-daily oral omadacycline, an
Autor:
Evan Loh, Joven Gonong, Anita Das, Monica Popescu, Judith N. Steenbergen, Roman Stets, Paul C. McGovern, Andrzej Madej, Paul B. Eckburg, Amy Manley, Evan Tzanis, William Nseir, Ismail Mitha, Lynne Garrity-Ryan, Courtney Kirsch
Publikováno v:
New England Journal of Medicine. 380:517-527
Background Omadacycline, a new once-daily aminomethylcycline antibiotic agent that can be administered intravenously or orally, reaches high concentrations in pulmonary tissues and is acti...
Publikováno v:
Open Forum Infectious Diseases
Background In animal models of Staphylococcus aureus infection, α-hemolysin has been shown to be a key virulence factor. Treatment of S. aureus with subinhibitory levels of protein synthesis inhibitors can decrease α-hemolysin expression. Omadacycl
Autor:
Amy Manley, Courtney Kirsch, Paul C. McGovern, Antoni Torres, Lynne Garrity-Ryan, Anita Das, Judith N. Steenbergen, Marla Curran, Paul B. Eckburg, Evan Tzanis
Publikováno v:
International Journal of Infectious Diseases, Vol 104, Iss, Pp 501-509 (2021)
Objective Community-acquired bacterial pneumonia (CABP) is a major clinical burden worldwide. In the phase III OPTIC study (NCT02531438) in CABP, omadacycline was found to be non-inferior to moxifloxacin for investigator-assessed clinical response (I
Autor:
Lynne Garrity-Ryan, Evan Loh
Publikováno v:
New England Journal of Medicine. 380:2072-2074
Autor:
Stephen Bai, Amy Manley, J Scott Overcash, Judith N. Steenbergen, Evan Tzanis, Lynne Garrity-Ryan, Surya Chitra, Pouru Bhiwandi
Publikováno v:
Antimicrobial Agents and Chemotherapy
Omadacycline, an aminomethylcycline antibiotic, is approved as once-daily intravenous (i.v.) and oral (p.o.) monotherapy for acute bacterial skin and skin structure infections and for community-acquired bacterial pneumonia, and it is under developmen
Autor:
Julio A. Ramirez, Evan Tzanis, Amy Manley, Lynne Garrity-Ryan, Surya Chitra, Courtney Kirsch, Paul C. McGovern
Publikováno v:
Respiratory infections.
Autor:
Amy Manley, Evan Tzanis, Stephen Villano, Jolene Kay Berg, Lynne Garrity-Ryan, Surya Chitra, Stephen Bai
Publikováno v:
Antimicrobial Agents and Chemotherapy
Many antibiotics require dose adjustments in patients with renal impairment and/or in those undergoing hemodialysis. Omadacycline, the first aminomethylcycline antibiotic in late-stage clinical development, displays activity against a broad spectrum